Inflammatory bowel disease (IBD) is a chronic and non-specific inflammatory disease of the intestine, including Crohn's disease (CD) and ulcerative colitis (UC), and its etiology remains unclear. In recent years, with changes in people's living environment and dietary habits, and the improvement of diagnostic levels, the incidence of IBD worldwide has been increasing rapidly, placing pressure on the medical system, and making the situation more severe. The diversity and stability of intestinal microorganisms are important factors influencing IBD, and the development of IBD therapeutics based on microorganisms has potential. Many researchers are developing engineered strains of bacteria for the treatment of IBD, and most of the research is still in the pre-clinical stage.
Read Full Article: probiotics in ibd
